An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A former senior FDA lawyer, Howard Sklamberg, spoke about how the Food and Drug Administration (FDA) watches — and sometimes doesn’t fully control — the practice of compounding peptides for women’s health. In plain terms: some clinics and pharmacies mix up custom versions of peptide drugs instead of using factory-made medicines, and Sklamberg discussed where the FDA has authority, where it doesn’t, and why that matters for patients and doctors. When people say “peptide” here, think of a short string of amino acids — the tiny building blocks that make up proteins. Some medically useful peptides act like signals in the body, nudging cells to do things such as release hormones or change how tissues behave. There are well-known, approved peptide drugs (sold after clinical trials), and there are compounded peptides, which are made individually by a pharmacist or clinic based on a prescription. Compounded versions are not always tested the same way as factory-made drugs. Sklamberg’s commentary focuses on the legal and regulatory picture, not on a new scientific study of effectiveness. He explained how the FDA’s power to regulate compounded drugs has limits. When a pharmacy mixes a drug for a specific patient based on a doctor’s order, federal rules and state pharmacy boards play a role; the FDA tends to step in mainly when there’s a broader public-health concern, like unsafe products or interstate distribution. The discussion highlights that oversight can be uneven: some compounded peptides are made and used widely even though they haven’t gone through the formal approval process that checks safety, dosage, and manufacturing quality at scale. Why this matters is practical. Patients — especially in areas like fertility, hormone therapy, or dermatology — might be offered compounded peptides as newer or cheaper options. But those products can vary in quality, strength, and purity. For a person considering such treatments, it’s important to know whether the peptide has been thoroughly tested, who made it, and what controls are in place. Clinicians and clinics also need clarity on legal responsibilities and on when the FDA might intervene. There are clear caveats and risks. Compounded peptides may carry risks of contamination, incorrect dosing, or inaccurate labeling because they don’t always follow the same manufacturing checks as approved drugs. They may also lack robust clinical trial data proving they work or are safe for the intended use. Regulatory status can be murky: some compounded products are lawful under certain conditions, but others could run afoul of rules if they’re essentially copies of approved drugs or are distributed widely. People with serious conditions or those who are pregnant should be especially cautious and discuss options with a licensed clinician. Bottom line: Sklamberg’s comments remind us that compounded peptides exist in a regulatory grey zone — they’re accessible and used in women’s health, but they don’t always have the same safety and oversight protections as approved drugs.
Source: Arnold & Porter